Gilead ties up with generic drugmakers in India, Pakistan for coronavirus COVID-19 drug supply
Image Credit: shortpedia
Gilead Sciences Inc said it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir. The pacts allow the companies - Jubilant Life Sciences Ltd , Cipla Ltd , Hetero Labs Ltd, Mylan NV and Ferozsons Laboratories Ltd - to make and sell the drug in 127 countries. The licensees will also set their own prices for the product.